Nose to Brain Drug Delivery System

Gayatri D Patil; Aditya R Nikam; Paresh A. Patil; Aakash D. Sonar

doi:10.52711/0975-4377.2021.00054

Research Journal of Pharmaceutical Dosage Forms and Technology

ISSN

0975-4377 (Online)
0975-234X (Print)

Submit Article

Nose to Brain Drug Delivery System

Author(s): Gayatri D Patil, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar

Email(s): drjigarvyas@gmail.com

DOI: 10.52711/0975-4377.2021.00054

Address: Gayatri D Patil, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar
Ahinsa Institute of Pharmacy, Dondaicha 425408.
*Corresponding Author

Published In: Volume - 13, Issue - 4, Year - 2021

View HTML

View PDF

ABSTRACT:
The treatment of brain disorders is particularly challenging due to the presence of a variety of formidable obstacles to deliver drugs selectively and effectively to the brain. Blood-brain-barrier (BBB) constitutes the major obstacle to the uptake of drugs into the brain following systemic administration. An intranasal delivery provides some drugs with short channels to bypass the blood-brain barrier (BBB), especially for those with fairly low brain concentrations after a routine delivery, thus greatly enhancing the therapeutic effect on brain diseases. The nasal mucosa is nearby the brain, cerebrospinal fluid (CSF) and the drug concentrations can exceed plasma concentrations. a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia, and a reduction in drug metabolism in the nasal cavity. Indications where nose-to-brain products are likely to emerge first include the following: neurodegeneration, post-traumatic stress disorder, pain, and glioblastoma.

Keywords:

Cite this article:
Gayatri D Patil, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar. Nose to Brain Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(4):335-0. doi: 10.52711/0975-4377.2021.00054

Cite(Electronic):
Gayatri D Patil, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar. Nose to Brain Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(4):335-0. doi: 10.52711/0975-4377.2021.00054 Available on: https://rjpdft.com/AbstractView.aspx?PID=2021-13-4-11

REFERENCES:
1.   Pardridge W.M., Blood-brain barrier drug targeting: the future of brain drug development. Molecular interventions, 2003; 3(2): 91-103
2.   GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16: 877–897.
3.   Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control. Rel. 2003; 87: 187-198
4.   Mathers CD and Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
5.   Smith EL, Hill RL, Borman A. Activity of insulin degraded by aminopeptidase. Biochim. Biophy. Acta. 1958; 29: 207-208.
6.   Dominique D, Gilles P. Nasal administration: a tool for tomorrow’s systemic administration of drugs. Drug Dev. Ind. Pharm. 1993; 19: 101-122.
7.   Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al.; CDBE2010 Study Group (2011) Cost of disorders of the brain in Europe 2010 [published correction appears in Eur Neuropsychopharmacol (2012) 22: 237–238]. Eur Neuropsychopharmacol 21: 718–779.
8.   Daneman R and Prat A (2015) The blood-brain barrier. Cold Spring Harb Perspect Biol 7:a020412.
9.   Sahin-Yilmaz A and Naclerio RM (2011) Anatomy and physiology of the upper airway. Proc Am Thorac Soc 8: 31–39.
10.   Illum L. Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz E, Chickering DE, Lehr CME, editors. Fundamentals, Novel Approaches and Development. New York. Marcel Dekker; 1999; 507-539.
11.   Ingemann M, Frokjaer S, Hovgaard L, Brøndsted H. Peptide and Protein Drug Delivery Systems for Non-Parenteral Routes of Administration. In: Frokjaer S, Hovgaard L, editors. Pharmaceutical Formulation Development of Peptides and Proteins. Philadelphia, PA, USA. Taylor and Francis; 2000. p.189.
12.   Thorne R.G., Emory C.R., Ala T.A. and Fery W.H., Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res, 1995; 692(1-2): 278- 282,
13.   Lochhead JJ and Thorne RG (2012) intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64: 614–628.
14.   Thorne RG, Hanson LR, Ross TM, Tung D, and Frey WH II (2008) Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152: 785–797.
15.   Davis SS. Further development in nasal drug delivery. Pharmaceutical Science and Technology Today. 1999; 2: 265-266.
16.   Hamidovic A, Khafaja M, Brandon V, Anderson J, Ray G, Allan AM, and Burge MR (2017) Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial. Mol Psychiatry 22: 1413–1421.
17.   D‟Souza R, Mutalik S, Venkatesh M, Vidyasagar S, Udupa N. Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS PharmSciTech. 2005; 6: E184-E189
18.   Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. J. Pharm. Sci. 2006; 54: 570-580.
19.   R.S Bhanushali, M M Gatne, R V Gaikwad, A N Bajaj, M a Morde. Nano emulsion based intranasal delivery of anti migrane drugs for nose to brain targeting. Tndian journal of P’cal sciences. 2009; 71(6): 707-709
20.   Carafa, M. Santucai and Lucania, G (2002) Lidocaine loaded non-ionic surfactant vescicles: characterization & in vitro permeation studies. Int J Pharm 231: 21-32.
21.   Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 2009; 379: 146-157
22.   Chapman CD, Frey WH II, Craft S, Danielyan L, Hallschmid M, Schiöth HB, and Benedict C (2013) Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 30: 2475–2484.
23.   Mayank, Chaturvedi., Manish, Kumar., Kamla Pathak. (2011). A review on mucoadhesive polymer used in nasal drug delivery system. J. Adv Pharm Technol Res. 2(4): 215–222
24.   Junginger, H.E. (1956). Mucoadhesive hydrogels. Pharmazeutische Industrie. 53: 1056-1065.
25.   Mayank, Chaturvedi., Manish, Kumar., Kamla Pathak. (2011). A review on mucoadhesive polymer used in nasal drug delivery system. J. Adv Pharm Technol Res. 2(4): 215-222
26.   Arora, P., Shar34ma, S., Garg, S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7(18): 967- 975
27.   Anaisa, Pires., Ana, Fortuna., Gilberto, Alve., Amilcar, Falcao. (2009). Intranasal Drug Delivery: How, Why and What for. J Pharm Pharmaceut Sci 12(3): 288 – 311
28.   Utkarshini, Anand., Tiam, Feridooni., Remigius U. (2012) Novel Mucoadhesive Polymers for Nasal Drug Delivery. Recent Advances in Novel Drug Carrier Systems. 315-330
29.   Arora, P., Sharma, S., Garg, S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7(18): 967- 975
30.   Born J, Lange T, Kern W, McGregor GP, Bickel U, and Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5: 514–516.
31.   Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. J. Pharm. Sci. 2006; 54:570-580.
32.   Kwatikar PS, kulkarni NP, yadav SP and sakarkar DM, formulation and evaluation of an anti-epileptic drug loaded microemulsion for nose to brain delivery, asian J. Pharmaceutics, april-june, 2009.
33.   Florence K, Agrawal HG and Misra A. Intranasal delivery of clobazam for treatment of status epileptics.
34.   T. Yamada, “The potential of the nasal mucosa route for emergency drug administration via a high-pressure needleless injection system,” Anesthesia Progress, 51(2): pp. 56–61, 2004.
35.   G. Rathnam, N. Narayanan, and R. Ilavarasan, “Carbopol-based gels for nasal delivery of progesterone,” AAPS PharmSciTech, 2008;9(4): pp. 1078–1082.
36.   W. Ying, G. Wei, D. Wang et al., “Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia,” Frontiers in Bioscience, 2007; 12(7): pp. 2728–2734.
37.   G. Wei, D. Wang, H. Lu et al., “Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury,” Frontiers in Bioscience, 2007; 12(13): pp. 4986–4996.
38.   A. G. de Boer, I. C. J. van der Sandt, and P. J. Gaillard, “The role of drug transporters at the blood-brain barrier,” Annual Review of Pharmacology and Toxicology, 2003; 43: pp. 629–656.

Recomonded Articles:

Formulation and Evaluation of Tolperisone Hydrochloride Sustained Release Tablet

Author(s): Domendra Sahu, Shekhar Verma , Ravindra D. Dubey

DOI: Access: Open Access Read More

Transdermal Drug Delivery System of Antidiabetic Drugs: A Review

Author(s): Swapnil T. Deshpande, P. S. Vishwe, Rohit D. Shah, Swati S. Korabu, Bhakti R. Chorghe, DG Baheti

DOI: Access: Open Access Read More

Isolation and evaluation of Basella alba linn. Leaf mucilage as release retardant in tablet formulation

Author(s): Yamunappa, Ravi Kumar, Pooja Shetty, Prathibha Suvarna, Narayana Swamy VB

DOI: 10.5958/0975-4377.2016.00012.4 Access: Open Access Read More

Formulation and Evaluation of Fast Dissolving Tablets of Trimetazidine Dihydrochloride Using Natural and Synthetic Superdisintegrants

Author(s): Simila Madathil, RaviKumar, Anju Govind, Mercy Mathew, Narayana Swamy VB

DOI: 10.5958/0975-4377.2016.00013.6 Access: Open Access Read More

Self Microemulsifying Drug Delivery System (SMEDDS): A Novel Approach to Improve the Therapeutic Efficacy of Orally Administered Drug

Author(s): Kritika Kanoujia, Chandraprabha Dewangan, Ayushi Masih, Dipti Sinha, Divya Oraon, Manisha Jaiswal, Monika Sahu, Ranjeeta Kumari, Sapna Pradhan, Ravi Suman, Rajkishan Dewangan, Roman Banjare, Pradeep Paikra, Mukesh Rawtiya, Mukta Agrawal, Ajazuddin, D. K. Tripathi, Amit Alexander

DOI: 10.5958/0975-4377.2018.00015.0 Access: Open Access Read More

Formulation and Evaluation of Fast Dissolving Tablets containing Clopidogrel bisulfate using holy basil seeds as a natural superdisintegrant

Author(s): Omprasad Nayakal, Prajakta Patil, Mangesh Bhutkar, Dheeraj Randive, Somnath Bhinge

DOI: 10.5958/0975-4377.2018.00032.0 Access: Open Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available
DOI: 10.5958/0975-4377